Oncology Central

Hepatocellular carcinoma and immune therapy, from a clinical perspective; where are we?

0

The incidence of hepatocellular carcinoma (HCC) has been reported to continue to increase in the past decades [1], however, we and other groups have found that this might be changing in the USA [2,3]. In our study – based on SEER data – there seemed to be a plateau in incidence rate around 2007, and that the rate of diagnosis in patients with smaller tumors (<5 cm) surpassed larger tumors around 2005. Despite these positive findings, less than 25% of patients received potentially curative treatment with liver transplantation, resection or ablation. In patients who are not candidates for curative treatments, options are limited to transcatheter arterial chemoembolization (TACE) for intermediate stage disease and, in the advanced disease setting, systemic therapy with sorafenib, the only US FDA-approved drug treatment [4,5]. 

To view restricted content, please:
Share:

Leave A Comment